LLC DRW Securities Sells Shares of Aditxt, Inc.

LLC DRW Securities sold 126,772 shares of Aditxt, Inc. (NasdaqCM: ADTX) on June 17, 2026. The transaction was valued at $1,267.72, with each share priced at $0.01.

What Changed in LLC DRW Securities' Aditxt, Inc. Position

On June 17, 2026, LLC DRW Securities sold off 126,772 shares of Aditxt, Inc. This move didn't involve a planned transaction and was carried out at a price of $0.01 per share, amounting to a total value of $1,267.72.

Other Institutional Activity in Aditxt, Inc.

In other institutional moves, Geode Capital Management, LLC added 434 shares of Aditxt, Inc., bringing its total to 434 shares valued at about $11,472. Morgan Stanley also increased its holdings by 296 shares, ending with 296 shares worth approximately $7,833. Conversely, Tower Research Capital LLC (TRC) reduced its position by 15 shares to hold 20 shares valued at $535. UBS Group AG and HRT Financial LP completely exited their positions, selling all their shares.

Aditxt, Inc. Stock Snapshot

Shares of Aditxt, Inc. are currently trading at $0.004. The company has a market capitalization of around $3,263.68. The stock has seen a 52-week low of $0.004 and a high of $53,453.52. Its 50-day moving average stands at $4.16, while the 200-day moving average is $3,857.65. The company's current ratio is 0.064, with a quick ratio of 0.021.

Insider Buying and Selling at Aditxt, Inc.

In addition to LLC DRW Securities' sale, HRT Financial LP was active with multiple transactions. On June 15, 2026, it purchased 2,114,344 shares at $0.01 per share. Earlier, on June 12, it bought 4,252,767 shares at $0.02 each. Conversely, on June 11, HRT Financial LP sold 2,833,463 shares at $0.01 each. Bank of America Corp /DE/ also had mixed activity on June 11, selling 15 shares at $0.01 and buying 7 shares at $0.0129.

Analysts Set New Price Targets

On September 6, 2023, H.C. Wainwright reiterated its 'buy' rating for Aditxt, Inc. and set a price target of $61.00.

About Aditxt, Inc.

Aditxt, Inc., headquartered in Mountain View, California, operates in the healthcare sector, specifically within the biotechnology industry. The company focuses on developing biopharmaceutical products, such as AditxtScore and FlowSpot, which help individuals understand and manage their immune profiles. Aditxt is also working on nucleic acid-based technologies for conditions like psoriasis and type-1 diabetes. The company is led by CEO Jeffrey M. Busch and employs around 26 people.

Bottom Line

LLC DRW Securities' recent sale of Aditxt, Inc. shares adds to the varied insider activities around the company. Aditxt, Inc. continues to be a focus for institutional investors, with varied positions among firms. While insider transactions offer some insight, they should be viewed as part of a broader investment picture.